Patents by Inventor Chengzhi Zhang

Chengzhi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200016148
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Application
    Filed: September 25, 2019
    Publication date: January 16, 2020
    Inventors: Chengzhi Zhang, Jim Kerr
  • Publication number: 20200000794
    Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 2, 2020
    Inventors: Thomas G. Gant, Manouchehr Shahbaz, Chengzhi Zhang
  • Patent number: 10513488
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 24, 2019
    Assignee: AUSPEX PHARMACEUTICALS, INC.
    Inventor: Chengzhi Zhang
  • Publication number: 20190374642
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: August 1, 2019
    Publication date: December 12, 2019
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • Publication number: 20190367492
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 5, 2019
    Inventors: Chengzhi ZHANG, Justin CHAKMA
  • Publication number: 20190328661
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Publication number: 20190205896
    Abstract: Embodiments of the present disclosure provide a terminal verification method, a terminal device and a computer readable storage medium. The method includes: reading machine verification parameters of a target terminal, determining that the target terminal is a fake in response to determining that the machine verification parameters of the target terminal satisfy a first condition, a second condition and a third condition, and displaying on a user interface of the target terminal that the target terminal is a fake.
    Type: Application
    Filed: June 6, 2018
    Publication date: July 4, 2019
    Applicant: ZHUHAI JUNTIAN ELECTRONIC TECHNOLOGY CO., LTD.
    Inventors: Zhengyang Duan, Honglei Chu, Liming Zhang, Chengzhi Jiang
  • Publication number: 20190205572
    Abstract: Embodiments of the present disclosure provide a terminal verification method, a terminal device and a computer readable storage medium. The method includes: reading machine verification parameters of a target terminal, determining that a system of the target terminal is modified in response to determining that the machine verification parameters of the target terminal satisfy a first condition, a second condition and a third condition, and displaying on a user interface of the target terminal that, the system of the target terminal is modified.
    Type: Application
    Filed: June 5, 2018
    Publication date: July 4, 2019
    Applicant: ZHUHAI JUNTIAN ELECTRONIC TECHNOLOGY CO., LTD.
    Inventors: Zhengyang Duan, Honglei Chu, Liming Zhang, Chengzhi Jiang
  • Publication number: 20190205522
    Abstract: Embodiments of the present disclosure provide a terminal verification method, a terminal device and a computer readable storage medium. The method includes: reading machine verification parameters of a target terminal, determining that the target terminal is incompletely configured in response to determining that the machine verification parameters of the target terminal satisfy a first condition and a second condition, and displaying on a user interface of the target terminal that, the target terminal is incompletely configured. The machine verification parameters of the target terminal include N terminal configuration parameters. The first condition includes abnormally reading the GPU manufacturer parameter and the GPU renderer parameter. The second condition includes normally reading a first group of terminal configuration parameters of the machine verification parameters of the target terminal. The first group of terminal configuration parameters includes (N?2) terminal configuration parameters.
    Type: Application
    Filed: June 6, 2018
    Publication date: July 4, 2019
    Applicant: ZHUHAI JUNTIAN ELECTRONIC TECHNOLOGY CO., LTD.
    Inventors: Zhengyang Duan, Honglei Chu, Liming Zhang, Chengzhi Jiang
  • Patent number: 10313738
    Abstract: A dynamic time window and cache method under the heterogeneous network transmission is provided, including adding Available_Time and Asset_Size attributes of the media content in the signaling or other places for the existing signaling at a MMT, so that the client terminal gets the time when the corresponding media content is available and the size of the media content; at the same time determining the network bandwidth and the network delay of the content from the broadband to the client under the current broadband network by the client; wherein the client terminal calculates the time interval for transmitting a request for caching in advance and the size of a cache window required by the terminal through the available time of the content of a broadband source and the delay of a broadband channel.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: June 4, 2019
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yiling Xu, Wenjun Zhang, Chengzhi Wang, Jun Sun, Yunfeng Guan, Dazhi He, Ning Liu
  • Publication number: 20190133935
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 9, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • Publication number: 20190092719
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 28, 2019
    Inventor: Chengzhi Zhang
  • Publication number: 20190083484
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 17, 2018
    Publication date: March 21, 2019
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • Publication number: 20190047951
    Abstract: Described are deuterium-substituted azetidine compounds of Formula (I), which are modulators of sphingosine 1-phosphate receptor. Also described are pharmaceutical compositions comprising the deuterium-substituted azetidine compounds, and methods of use thereof.
    Type: Application
    Filed: January 3, 2017
    Publication date: February 14, 2019
    Inventors: Chengzhi ZHANG, Justin CHAKMA
  • Patent number: 10167278
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 27, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, Justin Chakma
  • Patent number: 10166183
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • Publication number: 20180305298
    Abstract: Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, including neuropsychiatric disorders such as depression, epilepsy, schizophrenia, and Huntington's Disease, and use of said deuterated chlorokynurenines are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: October 25, 2018
    Inventors: Gregory R. OTT, Chengzhi ZHANG, Ralph LAUFER
  • Publication number: 20180289637
    Abstract: The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing these compounds, and methods of using these compounds.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Ralph Laufer, Chengzhi Zhang, Yi Wang
  • Publication number: 20180280511
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • Publication number: 20180265501
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: December 27, 2015
    Publication date: September 20, 2018
    Inventors: Chengzhi ZHANG, Justin CHAKMA